About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world
The SURMOUNT-4 trial, which tested the maximum tolerated dose approach, showed a mean weight loss of 26% to 26.6% at the highest doses participants could tolerate
Originally developed for type 2 diabetes and weight management, the GLP-1/GIP medication tirzepatide under the brand name Zepbound is now FDA-approved to treat obstructive sleep apnea
Tirzepatide is highly effective at suppressing appetite
The Potential Benefits of Microdosing Semaglutide and Tirzepatide Appetite Regulation & Satiety with Lower Side Effects Even at lower doses, GLP-1s can enhance satiety signals, reduce hunger, and improve portion control, potentially leading to gradual and sustainable weight loss without the intense gastrointestinal side effects sometimes seen at full doses
Labs are not required to start treatment, but the provider may request recent lab results from the last 12 months or ask the patient to bring records to a future appointment